Physician profile
Mark A Weissman
NPI 1144277492
$4,723.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,278 · 2020: $177 · 2021: $184 · 2022: $67.31 · 2023: $819 · 2024: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Travel and Lodging: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.25 |
| Travel and Lodging | $220.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micromed INC | $2,860.00 | 2019 | |
| Arthrex, INC. | $410.27 | 2023 | |
| Crossroads Extremity Systems, LLC | $239.76 | 2019 | |
| Bioventus LLC | $236.12 | 2019-2023 | Exogen Ultrasound Bone Healing System |
| Treace Medical Concepts, INC. | $214.37 | 2023-2024 | |
| Biotissue Holdings INC. | $160.82 | 2024 | |
| Ossio INC | $155.03 | 2023 | |
| Medline Industries LP | $139.44 | 2019-2021 | |
| Integra Lifesciences Corporation | $123.12 | 2019-2020 | |
| Acell, INC. | $68.96 | 2019-2020 | |
| Saxum Surgical, INC. | $36.88 | 2022 | |
| Janssen Scientific Affairs, LLC | $34.77 | 2023 | Xarelto |
| Tactile Systems Technology INC | $24.06 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.45 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.